Korea S.E.
06:00:00 2024-05-23 pm EDT
5-day change
1st Jan Change
829
KRW
+1.10%
-7.58%
+60.66%
Sumagen Co., Ltd. announced that it has received KRW 11.864430381 billion in funding from CUROCOM Co., Ltd.
On September 9, 2020, Sumagen Co., Ltd. closed the transaction.
CUROCOM Co., Ltd. announced that it has received KRW 8.5 billion in funding from CUROHOLDINGS Co., Ltd.
Dec. 18
CI
CUROCOM Co., Ltd. announced that it expects to receive KRW 8.5 billion in funding from CUROHOLDINGS Co., Ltd. and other investor
Dec. 10
CI
CUROCOM Co., Ltd.(KOSDAQ:A040350) dropped from S&P Global BMI Index
23-09-18
CI
CUROCOM Co., Ltd. announced that it has received KRW 6 billion in funding
23-08-06
CI
KIB Private Equity Co., Ltd, KIB CURO Second Acquisition Purpose Company completed the acquisition of a 37.359021% stake in Curo Co.,Ltd. from CUROCOM Co., Ltd., GNCO Co., Ltd., Q Capital Partners Co., Ltd., Qyuro F & B Co., Ltd. and Dongjun Kim
23-07-12
CI
CUROCOM Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
23-05-15
CI
KIB Private Equity Co., Ltd, KIB CURO Second Acquisition Purpose Company agreed to acquire a 37.359021% stake in Curo Co.,Ltd. from CUROCOM Co., Ltd., GNCO Co., Ltd., Q Capital Partners Co., Ltd., Qyuro F & B Co., Ltd. and Dongjun Kim for KRW 51.9 billion.
23-05-10
CI
CUROCOM Co., Ltd. announced that it has received KRW 6 billion in funding
22-03-29
CI
CUROCOM Co., Ltd. announced that it expects to receive KRW 6 billion in funding
22-03-23
CI
CUROCOM Co., Ltd. announced that it has received KRW 8.399998653 billion in funding from Curo Holdings Co., Ltd., Q Capital Partners Co., Ltd.
21-05-19
CI
CUROCOM Co., Ltd. announced that it expects to receive KRW 8.399998653 billion in funding from Curo Holdings Co., Ltd., Q Capital Partners Co., Ltd.
21-05-11
CI
Sumagen Co., Ltd. announced that it has received KRW 11.864430381 billion in funding from CUROCOM Co., Ltd.
20-09-08
CI
Sumagen Co., Ltd. announced that it expects to receive KRW 11.864430381 billion in funding from CUROCOM Co., Ltd.
20-09-07
CI
CUROCOM Co.,Ltd. announced that it has received KRW 3 billion in funding
20-08-05
CI
Qyuro F & B Co., Ltd. announced that it has received KRW 5.4 billion in funding from CUROCOM Co., Ltd. and other investors
20-07-28
CI
Qyuro F & B Co., Ltd. announced that it expects to receive KRW 5.4 billion in funding from CUROCOM Co.,Ltd. and other investors
20-07-26
CI
CUROCOM Co.Ltd. cancelled the acquisition of additional 18.53% stake in GNCO Co., Ltd..
18-07-13
CI
An undisclosed buyer cancelled the acquisition of 16.5% stake in Daekyung Machinery & Engineering Co., Ltd. from CUROCOM.Co.Ltd..
18-07-09
CI
CUROCOM.Co.Ltd. announced that it has received KRW 5.3 billion in funding from IN Asset Co., Ltd., J&J Assets Management Ltd, and other investors
17-11-30
CI
CUROCOM.Co.Ltd. announced that it expects to receive KRW 5.3 billion in funding from IN Asset Co., Ltd., J&J Assets Management Ltd, and other investors
17-11-29
CI
CUROCOM Co.Ltd. agreed to acquire additional 18.53% stake in GNCO Co., Ltd. for KRW 36 billion.
17-07-13
CI
GNCO Co., Ltd. announced that it has received KRW 35.99838 billion in funding from CUROCOM.Co.Ltd.
17-07-13
CI
CUROCOM.Co.Ltd. announced that it has received KRW 19.99888 billion in funding from K Partners Co., Ltd.
17-07-10
CI
CUROCOM.Co.Ltd. agreed to sell 16.5% stake in Daekyung Machinery & Engineering Co., Ltd. for KRW 9.6 billion.
17-07-09
CI
CUROCOM.Co.Ltd. agreed to acquire 40.8% stake in Daekyung Machinery & Engineering Co., Ltd. from Q Capital Partners Co., Ltd. for KRW 25.9 billion.
17-07-04
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
CreoSG Co Ltd, formerly Curocom Co Ltd, is a Korea-based company mainly engaged in solution business and distribution business. The Company operates through three segments. The Solutions Business segment is engaged in the development and provision of financial consulting and software for financial institutions. Additionally, the segment is engaged in the supply of core banking solutions BANCS-K framework and BANCS-K Package to banks and other financial institutions. The Distribution Business segment is engaged in the distribution business of computers, laptops, printers, and multi-function printers. The New Drug and Vaccine Development Business segment is engaged in the development of vaccines for acquired immunodeficiency syndrome(AIDS), corona virus disease 19 (COVID-19) vaccine and other infectious diseases, and research and development of super antibiotics for Staphylococcus aureus.
More about the company
1st Jan change
Capi.
+60.66% 86.76M +16.58% 338B +4.53% 152B +16.22% 59.22B +18.95% 34.22B +1.66% 30.08B +166.75% 29.88B +30.91% 21.64B +39.43% 14.13B -0.51% 13.99B
Enterprise Software
+951% of historical
More than 20 years
Our Experts
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
CREOSG CO.,LTD. 
